more

Mustang Bio (MBIO)

(Delayed Data from NSDQ)

$0.32 USD

-0.03 (-9.79%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.32 0.00 (1.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data

by Zacks Equity Research Published on June 13,2023

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.

Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet

by Zacks Equity Research Published on June 12,2023

The consensus price target hints at a 331.2% upside potential for Mustang Bio, Inc. (MBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MBIONegative Net Change

Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade

by Zacks Equity Research Published on May 26,2023

The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MBIONegative Net Change

Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing

by Zacks Equity Research Published on September 02,2022

Mustang Bio, Inc. (MBIO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

MBIONegative Net Change

Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on September 24,2021

Mustang Bio (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon.

MBIONegative Net Change

medical

Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock?

by Zacks Equity Research Published on December 04,2020

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

MBIONegative Net Change

medical

Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock?

by Zacks Equity Research Published on September 18,2020

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

MBIONegative Net Change

Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't?

by Zacks Equity Research Published on August 18,2020

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

MBIONegative Net Change

medical

Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session

by Zacks Equity Research Published on July 21,2020

Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't?

by Zacks Equity Research Published on June 17,2020

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

MBIONegative Net Change

Mustang Bio (MBIO) Jumps: Stock Rises 8.2%

by Zacks Equity Research Published on June 11,2020

Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

MBIONegative Net Change

medical

Is Mustang (MBIO) Stock a Solid Choice Right Now?

by Zacks Equity Research Published on May 21,2020

Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MBIONegative Net Change

medical

Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on December 27,2019

Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.